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Key messages
 ► What is the phenotype of patients with sarcoidosis 
presenting to hospital clinic in the UK?
 ► We made a number of conclusions from the data 
including that fatigue is a common complaint, use 
of endobronchial ultrasound-guided transbronchial 
needle aspirate is increasing over time and metho-
trexate is the most commonly used steroid-sparing 
agent.
 ► Sarcoidosis is a complex and challenging disease 
to diagnose and manage. Collection of registry 
data such as these will help standardise clinical 
practice and allow research to be targeted to areas 
where there is a larger disparity in how patients are 
managed.
AbstrAct
Introduction The British Thoracic Society Sarcoidosis 
Registry allows physicians to record clinical data after 
gaining written consent from patients. The registry’s aim is 
to phenotype sarcoidosis in the UK.
Methods Between February 2013 and July 2017, 
demographic details for 308 patients (with complete 
clinical data for 205 patients) presenting to 24 UK hospitals 
were recorded. This data was analysed to detail methods 
of presentation, diagnosis and management.
results Fatigue was a significant complaint, affecting 
30% of all patients. The most prevalent CT findings were 
nodules (in 77% of cases) with traction bronchiectasis 
(11%), distortion (9%) and ground glass (5%) less 
prominent. Of 205 patients with complete clinical data, 
only 64% had a diagnostic tissue biopsy. 35% of all 
patients underwent endobronchial ultrasound-guided 
transbronchial needle aspirate (EBUS-TBNA) with 15% 
having a transbronchial biopsy. Use of EBUS-TBNA showed 
an overall increase over time, from 28% of all patients in 
2013 to 43% in 2016. The most common steroid sparing 
treatment was methotrexate, but 42% of patients were not 
initiated on any pharmacological treatment at the time of 
inclusion.
Discussion Fatigue was common and has shown 
association with poor quality of life. We therefore suggest 
using a fatigue questionnaire as part of all new patient 
assessments. It may be that EBUS-TBNA should be 
reserved for cases of stage I or II disease where there is 
a reported higher yield than using transbronchial biopsy 
alone. Bronchoalveolar lavage was not widely used in 
our data, but it is generally a safe and useful adjunct and 
should be used more widely.
IntroDuctIon
Clinical data registries are useful in complex 
diseases where data can be collated for 
research purposes. To our knowledge, the 
British Thoracic Society (BTS) Sarcoidosis 
Registry is the only database in the world 
which allows physicians to record data after 
gaining written consent from patients with 
sarcoidosis. The aim of the registry is to 
record information to phenotype the disease 
in the UK.
European Respiratory Society (ERS)/Amer-
ican Thoracic Society/World Association of 
Sarcoidosis guidance on sarcoidosis is now 
almost 20 years old,1 and there is no recent 
international guidance on diagnosis and 
management of the disease. This is despite a 
number of more recent changes including the 
advent of endobronchial ultrasound-guided 
transbronchial needle aspirate (EBUS-TBNA) 
for tissue diagnosis which is not discussed in 
the previous ERS guidance.
A decision was therefore made by the 
BTS to perform an interim analysis on data 
collected to date with the specific aims of 
providing a clear interrogation of data from 
areas where the authors felt there was limited 
prior evidence for specific approaches in the 
diagnosis and management of sarcoidosis. 
As part of this process, a steering committee 
of the authors was formed to review all data 
collected to date and identify areas of greatest 
interest. Through this process, a number of 
areas were identified and these are presented 
here. There were three specific areas of 
interest to the committee: (1) the proportion 
of patients undergoing a tissue biopsy, (2) the 
type of biopsy performed in these patients 
and (3) the use of steroid-sparing agents in 
the management of sarcoidosis. The rationale 
for choosing these specific areas is associated 
with the lack of prior evidence regarding how 
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Figure 1 (A) Comorbidities at the time of diagnosis. (B) Presenting symptoms in sarcoidosis. (C) Sarcoidosis stage from 
chest radiograph. (D) Use of endobronchial ultrasound-guided transbronchial needle aspirate for diagnosis over time.
to make a diagnosis of sarcoidosis, in which patients to 
perform a biopsy and in cases where medication addi-
tional to steroids are needed, which agents are used.
The data is collected over the course of a single visit 
but may be updated onto the web portal over a period 
of time (eg, up to several months later once physicians 
have had time to collect all relevant clinical information 
for that case). As such, the data record is opened using 
demographic data only but is not marked as ‘complete’ 
until all the clinical information is entered and the 
record is locked. This resulted in approximately 70% 
of patients having a complete data set for this interim 
analysis (as detailed in the Methods section below), but 
over time this number is increasing, for example, as of 23 
November 2018, 75% of all entries have a complete data 
set. We anticipate that this percentage will rise over time 
as more cases are fully completed. The web tool to input 
data can be found at: https:// registry. brit- thoracic. org. 
uk/ An example of the full sarcoidosis registry tool with 
all data collection points is given in the online supple-
mentary appendix 1.
MethoDs
The Registry was launched on 1 February 2013 with full 
ethical approval (NRES reference:12/EE/0381). Partici-
pation is open to all UK Physicians. Patients must provide 
written consent. Data is collected at time of presentation 
to the clinic and entered onto a web-based platform. 
The registry is associated with the Idiopathic Pulmonary 
Fibrosis registry and this means that clinicians may sign 
up for both registries together.
Between February 2013 and July 2017, demographic 
details for 308 patients (with complete clinical data 
for 205 patients) presenting to 24 UK hospitals were 
recorded (see online supplementary appendix 2 for full 
distribution by site). A steering committee was formed to 
review data for this interim analysis and make decisions 
on how to review and present the data. The manuscript 
was primarily written by MT and RC but all co-authors 
have reviewed and commented on the data presentation. 
The registry data is currently available for access by the 
BTS registry team and data is shared at international 
conferences.
results
A retrospective analysis of the 308 patients showed that 
mean age at inclusion was 50 years. Fifty-eight per cent 
were male and 64% Caucasian. Most had never smoked 
(64%) or were ex-smokers of >3 months duration (26%). 
Patients (3.7%) reported at least one first-degree rela-
tive with sarcoidosis. Forty-three per cent had no signifi-
cant comorbidities, while 14% had a diagnosis of essen-
tial hypertension and 11% type 2 diabetes (figure 1A). 
Respiratory symptoms were the predominant complaint 
with 55% having breathlessness and 48% cough. Fatigue 
was significant at 30% (figure 1B). The Medical Research 
Council (MRC) breathlessness score showed 48% of 
patients recorded as category I, 32% category II and 10% 
category III.
With respect to Scadding classification of chest radio-
graphs, these were recorded as stage 0 (8%), I (24%), 
II (29%), III (11%), IV (14%) with the remainder unre-
corded (figure 1C). The most prevalent CT findings 
were nodules (seen in 77% of cases) with traction bron-
chiectasis (11%), distortion (9%) and ground glass (5%) 
featuring less prominently.
Thillai M, et al. BMJ Open Resp Res 2019;6:e000357. doi:10.1136/bmjresp-2018-000357 3
Open access
Pulmonary function testing revealed predicted forced 
vital capacity at the time of inclusion ranging from 101.2% 
predicted for Scadding stage 0, to 92.8% predicted for 
stage IV. Mean predicted forced expiratory volume in one 
second showed a trend with stage from stage 0 (98.1%) 
through to stage IV (81.4%). Mean transfer factor for 
carbon monoxide at inclusion was 78.2% predicted. 
The most common blood abnormalities (both in 49% of 
cases) were lymphopenia and a raised serum ACE (>55 
IU/L) with a mean of 67.5 (range 3–221). Other blood 
abnormalities included a raised erythrocyte sedimenta-
tion rate (20%), abnormal liver function tests (17%) and 
raised serum calcium (10%).
Of 205 patients with complete clinical data, only 64% 
had a tissue biopsy, the remaining 36% had a clinic-radio-
logical diagnosis only. When biopsies were performed, 
79% were intrathoracic with extrathoracic lymph nodes 
(7%) and skin (6%) next most common sites. Thirty-five 
per cent of all patients in the registry underwent EBUS-
TBNA, 15% transbronchial biopsy (TBBX), 11% endo-
bronchial biopsy and 13% bronchoalveolar lavage (BAL). 
Twelve per cent of patients had a mediastinoscopy. Use of 
EBUS-TBNA showed an overall increase over time, from 
28% of all patients in 2013 to 43% of all patients in 2016 
(figure 1d).
At presentation, 39% of all patients were treated with 
oral corticosteroids. The second most common treat-
ments were methotrexate and inhaled corticosteroids 
(8% each). Forty-two per cent of patients were not initi-
ated on any pharmacological treatment at the time of 
diagnosis.
DIscussIon
We present data from 308 patients enrolled into the BTS 
Sarcoidosis Registry between 2013 and 2017. The aims of 
the analysis were review the entire data set and concen-
trate specifically on areas where the BTS committee felt 
there was the least amount of prior evidence. The two 
areas of greatest interest were regarding biopsy for diag-
nosis and the use of steroid sparing agents.
With regard to biopsy for sarcoidosis, until recently, 
there was debate about the role of EBUS-TBNA.2 
However, a recent study showed that as a single modality, 
EBUS-TBNA had the highest diagnostic yield at 74.5%, 
and addition of TBBX increased this to 91%.3 The choice 
and combination of diagnostic modalities is still unclear, 
but in our data EBUS-TBNA is more commonly used than 
TBBX. It may be that EBUS-TBNA should be reserved for 
cases of stage I or II disease where there is a reported 
higher yield than using TBBX alone.4 BAL was not widely 
used in our data. However, CD4:CD8 >3.5, in the absence 
of an increased proportion of other inflammatory cell 
types, may help support a diagnosis of possible sarcoid-
osis.5 BAL is generally a safe and useful adjunct and we 
argue that it should be used more widely in sarcoidosis, 
especially in cases where a transbronchial lung biopsy 
confers greater risk of bleeding or pneumothorax or in 
cases where extensive fibrosis means that a lung biopsy 
may have a low accuracy for diagnosis of sarcoidosis.
Identification of the both the proportion of registry 
patients who had a biopsy and in those who had a 
biopsy the type of procedure performed is an important 
finding from this data set. However, a further analysis 
will be needed to distinguish differing factors between 
the patients who had a biopsy and those who did not, as 
well as between the types of biopsy, for example, whether 
the extent of radiological changes influenced the type of 
bronchoscopic procedure performed.
The second main aim for this data analysis regarded 
the use of non-steroid agents in the pharmacological 
management of sarcoidosis and in this respect we feel our 
findings are important. Inhaled corticosteroids were used 
in 8% of registry patients and while there is evidence that 
an obstructive lung defect is present in almost a quarter 
of UK patients with sarcoidosis,6 studies have shown 
conflicting evidence with some showing improvement 
in lung function7 and others showing no benefit.8 One 
study with fluticasone showed no benefit against placebo 
but an improvement in cough.9 There are arguably no 
convincing studies to support the evidence of one steroid-
sparing drug over another and the choice of agent used is 
often influenced by local specialist experience. However, 
as with previous Delphi studies, methotrexate was our 
commonly used second-line drug.10
Two additional important findings from our analysis 
involve patients with a family history sarcoidosis and 
the symptoms recorded at time of presentation. In our 
data set, 3.7% of all patients reported a family history of 
sarcoidosis. The only previous UK study to report familial 
associations received questionnaires from 268 patients 
and found similar results in that 5.2% had at least one 
first-degree, second-degree or third-degree relative with 
sarcoidosis.11
With regard to symptoms, fatigue was common (30%) 
and has shown association with poor quality of life.12 
The aetiology is multifactorial including granuloma 
formation, depression, altered sleep patterns13 and use 
of corticosteroids.14 Fatigue is difficult to quantify, but 
the Fatigue Assessment Scale can differentiate between 
sarcoidosis fatigue and depression.15 We found no differ-
ence in fatigue presentation between men and women 
which contrasts with a recently published European 
phenotyping study of 2163 Caucasian patients where 
fatigue was seen at a higher incidence in women.16 
Although the registry does not record the likely cause 
of fatigue, given the prevalence in our data, we suggest 
routine use of a fatigue questionnaire both as part of all 
new patient appointments and as a longitudinal assess-
ment for patients who have difficult to manage fatigue.
The inferences of our findings are subject to some 
general limitations. Importantly, there is bias towards 
selective UK sites as although 24 hospitals entered data, it 
is possible that these represent sites where there are clini-
cians who have a specific interest in sarcoidosis. Indeed, 
of the 24 hospitals, 11 of them are designated tertiary 
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centres for interstitial lung diseases where there may be a 
greater access to specialist services. It would be important 
to capture further data from general respiratory clinics 
as well as from these specialist ones. Additionally, we do 
not have information on whether the absence of a biopsy 
influenced the decision to offer treatment, given that in 
some cases, physicians may be less likely to initiate phar-
macological treatment without a definite tissue diagnosis. 
Finally, few patients had follow-up data. More detailed 
longitudinal capture may prove useful in determining 
how often patients are followed up and when they can be 
discharged from specialist care.
Collection of data across multiple sites has both advan-
tages and limitations. In a disease such as sarcoidosis 
with significant variation in practice and a lack of clear 
evidence on diagnostic and management pathways, 
multisite data collection allows researchers to review 
variations in practice across different institutions and 
provide support to experts as they write the next set of 
clinical guidelines for the disease. However, a significant 
limitation is the lack of standardisation of data collection 
across sites. For instance, although patients may have the 
same investigations, the interpretation of some of these is 
not standardised, for example, the finding of abnormal-
ities on CT scans or the reporting of chest X-ray stage by 
Scadding classification. In order to mitigate against these 
variations, a central method of analysis and recording 
of all data is needed, but this will have significant logis-
tical and financial implications due to the need for data 
transfer, centralised reporting of imaging and review of 
clinical records. Such a centralised process would there-
fore improve the accuracy of data collection but may be 
prohibitively expensive to attain.
As the BTS registry grows in volume of patient records, 
a number of important new questions will need to be 
asked which will require further analysis of the data and 
may require new data points for entry. First, as detailed 
in the original aims for this analysis, there is no clear 
evidence on either the need for a biopsy or in cases 
where tissue is obtained, the type of biopsy used to diag-
nose disease. A future approach to the registry will be 
to perform a subanalysis on the radiographic differences 
between patients who had a biopsy and those in whom 
a diagnosis was made on clinico-radiological grounds 
alone. This analysis may require a more detailed collec-
tion of CT imaging findings but may allow us to deter-
mine the radiological phenotype of patients in whom a 
biopsy is performed, for example, in those without clas-
sical CT findings such as bilateral hilar lymphadenop-
athy alone with no concerning radiological or clinical 
features to suggest an alternative diagnosis. Addition-
ally, a further analysis is needed to determine whether 
the CT appearance influences the method of biopsy, 
for example, whether patients with predominantly hilar 
disease are subjected to EBUS-TBNA compared with 
those with predominantly parenchymal disease who may 
have TBBX. These findings would be important to both 
support future clinical statements in sarcoidosis and to 
design larger studies to help determine which type of 
biopsy to perform for a given phenotype of sarcoidosis.
Second, further questions need to be asked regarding 
the use of steroid-sparing agents. Our findings identified 
methotrexate as the most commonly used drug, but the 
registry currently has limited follow-up data on these 
patients. A targeted approach to specifically record longi-
tudinal data on patients prescribed steroid-sparing agents 
will allow us to record the clinical outcome, changes in 
lung function and blood biomarkers and the incidence 
of side effects including fibrosis or liver toxicity. Such 
data would be important in helping design future trials 
with both traditional steroid-sparing agents and any novel 
medications to determine their use in the pharmacolog-
ical management pathway for sarcoidosis.
Finally, it is noteworthy that none of the 308 patients 
were enrolled in clinical trials at the time of data capture. 
This may reflect the lack of available clinical trials for 
this disease, rather than a lack of enthusiasm for physi-
cians to enter patients into trials. Sarcoidosis is a complex 
disease and drug regimens used have not been proven in 
randomised controlled trials. New treatments are needed 
for patients with multisystem and progressive forms of 
disease. One important use of such a patient registry may 
be to address this gap by identifying patients for new clin-
ical trials.
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